AREDIA
LOE ApproachingNDAINJECTIONINJECTABLE
Approved
Sep 1998
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 21h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
AREDIA is a small-molecule injectable approved in 1998 for parenteral administration. The generic name and mechanism of action are not disclosed in available data. Patient population and specific indications require clarification from clinical records.
LOE Approaching
As a product approaching loss of exclusivity with moderate competitive pressure (30%), team restructuring and transition planning are likely underway.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
AREDIA has zero linked job openings, reflecting its mature LOE-approaching status and minimal hiring activity. Roles available are primarily defensive (market access, channel management) rather than growth-oriented, making this product a stabilization assignment rather than a career growth opportunity.
Brand ManagerField Sales Representative
Worked on AREDIA at Novartis? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.